This work reports the duration, safety, and viability of intravitreal slurry triamcinolone acetonide (TA; 1.0 mL of 40-mg/mL TA centrifuge concentrated into a 0.1-mL pellet) to treat cystoid macular edema (CME).
Methods:
A retrospective, consecutive review was conducted of patients undergoing intravitreal slurry TA injections, July 2009 to December 2018.
Results:
In 143 eyes of 120 patients, slurry TA resolved CME for a mean of 327.15 (SD = 213.11) days, or 10.76 (SD = 7.00) months, per intravitreal injection (n = 466). In 100 eyes requiring multiple injections (n = 423), mean duration was 270.95 (SD = 177.14) days, or 8.91 (SD = 5.82) months, between injections. In 43 single-injection eyes, duration was 749.30 (SD = 483.17) days, or 24.63 (SD = 15.88) months. Mean duration decreased from 337.89 (SD = 210.46) days, or 11.11 (SD = 6.92) months, in nonvitrectomized eyes to 279.74 (SD 179.63) days, or 9.20 (SD = 5.91) months, in vitrectomized eyes (n = 74 injections, t = 2.24, P = .014, 1-tailed). Central foveal thickness as shown on optical coherence tomography decreased by 173.89μ (SD = 147.56μ), from 459.16μ (SD = 47.14μ) to 285.27μ (SD = 77.27μ; t = –25.31, P < .001), within 43.41 days (SD = 36.86). Visual acuity improved from 20/100 (logMAR 0.70, SD = 0.33) to 20/74 (logMAR 0.57, SD = 0.31; SD = 0.21; t = –11.01, P < .001), within 33.98 (SD 24.98) days. Fifteen of 31 phakic eyes (48.39%) underwent cataract extraction. Fifty-seven eyes (39.86%) developed a steroid response (> 10 mm Hg increase from baseline) 94.79 days (SD = 85.52 days), or 3.11 (SD = 2.81) months, following injection.
Conclusions:
A single injection of slurry TA lasted on average 10.76 months with significant improvement of CME and visual acuity. Adverse ocular effects were comparable to currently available, long-term, implantable steroids. Slurry TA appears to be an easily reproducible, safe, and cost-effective alternative to long-term intraocular steroid delivery.
KimHYChoiMYKimYS, et al.Triamcinolone acetonide protects the rat retina from STZ-induced acute inflammation and early vascular leakage. Life Sci. 2007;81(14):1167–1173. doi:10.1016/j.lfs.2007.08.024
2.
KimYHChungIYChoiMY, et al.Triamcinolone suppresses retinal vascular pathology via a potent interruption of proinflammatory signal-regulated activation of VEGF during a relative hypoxia. Neurobiol Dis. 2007;26(3):569–576. doi:10.1016/j.nbd.2007.02.002
3.
UmlandSPNahrebneDKRazacS, et al.The inhibitory effects of topically active glucocorticoids on IL-4, IL-5, and interferon-gamma production by cultured primary CD4+ T cells. J Allergy Clin Immunol. 1997;100(4):511–519. doi:10.1016/s0091-6749(97)70144-1
4.
FlomanNZorU. Mechanism of steroid action in ocular inflammation: inhibition of prostaglandin production. Invest Ophthalmol Vis Sci. 1977;16(1):69–73. doi:10.1016/0090-6980(76)90021-6
5.
JonasJB. Intravitreal triamcinolone acetonide: a change in a paradigm. Ophthalmic Res. 2006;38(4):218–245. doi:10.1159/000093796
6.
MachemerRSugitaGTanoY. Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc. 1979;77:171–180.
SaraoVVerittiDBosciaFLanzettaP. Intravitreal steroids for the treatment of retinal diseases. ScientificWorldJournal. 2014;2014:989501. doi:10.1155/2014/989501
10.
ScholesGNBrienWJAbramsGWKubicekMF. Clearance of triamcinolone from vitreous. Arch Ophthalmol. 1985;103(10):1567–1569. doi:10.1001/archopht.1985.01050100143037
11.
SchwartzSGFlynnHWJrBeerP. Intravitreal triamcinolone acetonide use in diabetic macular edema: illustrative cases. Ophthalmic Surg Lasers Imaging. Published online March 9, 2010. doi:10.3928/15428877-20100215-95
12.
BeerPMBakriSJSinghRJLiuWPetersGBMillerM. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110(4):681–686. doi:10.1016/S0161-6420(02)01969-3
13.
Lecleire-ColletAOffretOGaucherDAudrenFHaouchineBMassinP. Full-thickness macular hole in a patient with diabetic cystoid macular oedema treated by intravitreal triamcinolone injections. Acta Ophthalmol Scand. 2007;85(7):795–798. doi:10.1111/j.1600-0420.2007.00925.x
14.
AudrenFLecleire-ColletAErginayA, et al.Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol. 2006;142(5):794–799. doi:10.1016/j.ajo.2006.06.011
15.
AudrenFTodMMassinP, et al.Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Invest Ophthalmol Vis Sci. 2004;45(10):3435–3441. doi:10.1167/iovs.03-1110
16.
OberMDValijanS. The duration of effect of centrifuge concentrated intravitreal triamcinolone acetonide. Retina. 2013;33(4):867–872. doi:10.1097/IAE.0b013e31826b0bee
WatanabeATsuzukiAAraiKGekkaTKohzakiKTsuneokaH. Efficacy of intravitreal triamcinolone acetonide for diabetic macular edema after vitrectomy. J Ocul Pharmacol Ther. 2016;32(1):38–43. doi:10.1089/jop.2015.0045
19.
HussainRMCiullaTACiullaLMSinkBHarrisA. Efficacy of dexamethasone intravitreal implant for refractory macular edema caused by retinal vein occlusion. Retin Cases Brief Rep. 2018;12(4):294–299. doi:10.1097/ICB.0000000000000496
20.
LimLLMorrisonJLConstantinouM, et al.Diabetic macular edema at the time of cataract surgery trial: a prospective, randomized clinical trial of intravitreous bevacizumab versus triamcinolone in patients with diabetic macular oedema at the time of cataract surgery—preliminary 6 month results. Clin Exp Ophthalmol. 2016;44(4):233–242. doi:10.1111/ceo.12720
21.
JaffeGJLinPKeenanRTAshtonPSkalakCStinnettSS. Injectable fluocinolone acetonide long-acting implant for noninfectious intermediate uveitis, posterior uveitis, and panuveitis: two-year results. Ophthalmology. 2016;123(9):1940–1948. doi:10.1016/j.ophtha.2016.05.025
22.
PrietoEVispeEOtín-MalladaS, et al.Determination of three corticosteroids in the biologic matrix of vitreous humor by HPLC-tandem mass spectrometry: method development and validation. Curr Eye Res. 2017;42(2):244–251. doi:10.1080/02713683.2016.1183795
Fassbender AdeniranJMJusufbegovicDSchaalS. Common and rare ocular side-effects of the dexamethasone implant. Ocul Immunol Inflamm. 2017;25(6):834–840. doi:10.1080/09273948.2016.1184284
25.
KocakNOzturkTKarahanEKaynakS. Anterior migration of dexamethasone implant in a pseudophakic patient with intact posterior capsule. Indian J Ophthalmol. 2014;62(11):1086–1088. doi:10.4103/0301-4738.146763
26.
PapastavrouVTZambarakjiHDooleyIEleftheriadisHJacksonTL. Observation: fluocinolone acetonide (Iluvien) implant migration into the anterior chamber. Retin Cases Brief Rep. 2017;11(1):44–46. doi:10.1097/ICB.0000000000000284
27.
RahimyEKhuranaRN. Anterior segment migration of dexamethasone implant: risk factors, complications, and management. Curr Opin Ophthalmol. 2017;28(3):246–251. doi:10.1097/ICU.0000000000000365
28.
SteltonCRTownsendJPetersonLTKhuranaRNYehS. Surgical management of anterior chamber migration of a dexamethasone intravitreal implant. Ophthalmic Surg Lasers Imaging Retina. 2015;46(7):756–759. doi:10.3928/23258160-20150730-11
29.
JonasJBKreissigISpandauUHHarderB. Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. Am J Ophthalmol. 2006;141(3):579–580. doi:10.1016/j.ajo.2005.10.007
30.
JonasJBRenschF. Decreased retinal vein diameter after intravitreal triamcinolone for retinal vein occlusions. Br J Ophthalmol. 2007;91(12):1711–1712. doi:10.1136/bjo.2007.116558
31.
ChinHSKimTHMoonYSOhJH. A convenient method to concentrate triamcinolone acetonide for intravitreal injection. Retina. 2005;25(8):1107–1108. doi:10.1097/00006982-200512000-00026
32.
SongZGaoHLiuHSunX. Metabolomics of rabbit aqueous humor after administration of glucocorticosteroid. Curr Eye Res. 2011;36(6):563–570. doi:10.3109/02713683.2011.566410
33.
Hernaez-OrtegaMCSoto-PedreE. Purification of triamcinolone acetonide suspension for intravitreal use: the centrifugation method. J Ocul Pharmacol Ther. 2009;25(5):473–474. doi:10.1089/jop.2009.0017
34.
Soto-PedreEHernaez-OrtegaMC. A concentrating method for intravitreal triamcinolone acetonide (TA) injection. Retina. 2006;26(5):590; author reply 590-591. doi:10.1097/00006982-200605000-00019
35.
García-ArumíJBoixaderaAGiraltJ. Comparison of different techniques for purification of triamcinolone acetonide suspension for intravitreal use. Br J Ophthalmol. 2005;89(9):1112–1114. doi:10.1136/bjo.2005.067744
36.
ChangYCWuWC. Intravitreal triamcinolone acetonide for the management of papillophlebitis and associated macular edema. Int Ophthalmol. 2008;28(4):291–296. doi:10.1007/s10792-007-9128-8
37.
JonasJBSchlichtenbredeF. Visual acuity and intraocular pressure after high-dose intravitreal triamcinolone acetonide in selected ocular diseases. Eye (Lond). 2008;22(7):869–873. doi:10.1038/sj.eye.6702734
38.
JonasJB. Intravitreal triamcinolone acetonide for diabetic retinopathy. Dev Ophthalmol. 2007;39:96–110. doi:10.1159/000098502
39.
SpandauUHDerseMSchmitz-ValckenbergPPapoulisCJonasJB. Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema. Br J Ophthalmol. 2005;89(8):999–1003. doi:10.1136/bjo.2004.062596
40.
ChinHSParkTSMoonYSOhJH. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina. 2005;25(5):556–560. doi:10.1097/00006982-200507000-00002
41.
Chang-LinJEBurkeJAPengQ, et al.Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci. 2011;52:4605–4609. doi:10.1167/iovs.10-6387
42.
ÇevikSGYılmazSÇevikMTAkalpFDAvcıR. Comparison of the effect of intravitreal dexamethasone implant in vitrectomized and nonvitrectomized eyes for the treatment of diabetic macular edema. J Ophthalmol. 2018;2018:1757494. doi:10.1155/2018/1757494
43.
ShaikhAHPetersenMRSiskRAFosterRERiemannCDShaikhAH. Comparative effectiveness of the dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to central retinal vein occlusion. Ophthalmic Surg Lasers Imaging Retina. 2013;44(1):28–33. doi:10.3928/23258160-20121221-09
44.
PelegrínLde la MazaMSMolinsBRíosJAdánA. Long-term evaluation of dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to non-infectious uveitis. Eye (Lond). 2015;29(7):943–950. doi:10.1038/eye.2015.73
45.
CampochiaroPABrownDMPearsonA, et al.Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125–2132. doi:10.1016/j.ophtha.2012.04.030
46.
JaffeGFMartinDCallananD, et al.Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006;113(6):1020–1027. doi:10.1016/j.ophtha.2006.02.021
47.
HallerJABandelloFBelfortRJr; et al.OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6):1134–1146.e3. doi:10.1016/j.ophtha.2010.03.032
48.
JaffeGJFosterCSPavesioCE, et al.Effect of an injectable fluocinolone acetonide insert on recurrence rates in chronic noninfectious uveitis affecting the posterior segment: twelve month results. Ophthalmology. 2019;128(4):601–610. doi:10.1016/j.ophtha.2018.10.033
49.
ThorneJESugarEAHolbrookJT; et al.Multicenter Uveitis Steroid Treatment Trial Research Group. Periocular triamcinolone vs. intravitreal triamcinolone vs. intravitreal dexamethasone implant for the treatment of uveitic macular edema: the Periocular vs. Intravitreal Corticosteroids for Uveitic Macular Edema (POINT) trial. Ophthalmology. 2019;126(2):283–295. doi:10.1016/j.ophtha.2018.08.021
50.
TammewarAMChengLKayikciogluOR, et al.Comparison of 4 mg versus 20 mg intravitreal triamcinolone acetonide injections. Br J Ophthalmol. 2008;92(6):810–813. doi:10.1136/bjo.2007.126227
51.
ScottIUIpMSVan VeldhuisenPC, et al.A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009;127(9):1115–1128. doi:10.1001/archophthalmol.2009.233
52.
DodwellDGKrimmelDAde FiebreCM. Sterile endophthalmitis rates and particle size analyses of different formulations of triamcinolone acetonide. Clin Ophthalmol. 2015;9:1033–1040. doi:10.2147/OPTH.S82562
53.
LamAGargSJSpirnMJFinemanMSSivalingamA. Sterile endophthalmitis following intravitreal injection of preservative-free triamcinolone acetonide. Retin Cases Brief Rep. 2008;2(3):228–230. doi:10.1097/ICB.0b013e31811324a0
54.
WangLCYangCM. Sterile endophthalmitis following intravitreal injection of triamcinolone acetonide. Ocul Immunol Inflamm. 2005;13(4):295–300. doi:10.1080/09273940590951007
55.
OtsukaHKawanoHSonodaSNakamuraMSakamotoT. Particle-induced endophthalmitis: possible mechanisms of sterile endophthalmitis after intravitreal triamcinolone. Invest Ophthalmol Vis Sci. 2013;54(3):1758–1766. doi:10.1167/iovs.12-11247
56.
SpitzerMSMlynczakTSchultheissM, et al.Preservative-free triamcinolone acetonide injectable suspension versus “traditional” triamcinolone preparations: impact of aggregate size on retinal biocompatibility. Retina. 2011;31(10):2050–2057. doi:10.1097/IAE.0b013e318214d076
XuDStarrMRBoucherNChiangA, et al.Real-world vitreoretinal practice patterns during the 2020 COVID-19 pandemic: a nationwide, aggregated health record analysis. Curr Opin Ophthalmol. 2020; 31(5):427–434. doi:10.1097/ICU.0000000000000692
